

Figure 5

A

Drug	Associated model parameter	Targets	Associated genomic alterations	Weight
OSI-906	k ERK, RSKp90	IGF1R	MYC->PDK1, SMAD2	
OSI-906	k MEK, ERK	IGF1R	MYC->PDK1, SMAD2	
BMS-345541	τ cJun	IKBKB	PARK2-lcJun; MYC->PDK1, SMAD2	
HG-5-88-01	k IKK, ERK	EGFR		
OSI-906	τ RPS6	IGF1R	MYC->PDK1, SMAD2	
BMS-345541	k EGFR, PI3K	IKBKB	PARK2-lcJun; MYC->PDK1, SMAD2	
SB590885	τ IkBa	BRAF		
AZD6244	τ GSK3	MEK		
HG-5-88-01	k MEK, ERK	EGFR		
PD-0325901	k IKK, ERK	MEK		
HG-5-88-01	k ERK, RSKp90	EGFR		
BMS-754807	τ RPS6	IGF1R	MYC->PDK1, SMAD2	
SB590885	k ERK, RPS6	BRAF		
(5Z)-7-Oxozeaenol	k IKK, TBK1	MAP3K7 (TAK1)		
BMS-345541	k PI3K, PAK1	IKBKB	PARK2-lcJun; MYC->PDK1, SMAD2	
AZD6244	k IKK, ERK	MEK		
AZD6244	k RSKp90, GSK3	MEK		
(5Z)-7-Oxozeaenol	k TGFRb, SMAD2	MAP3K7 (TAK1)		
RDEA119	k IKK, ERK	MEK		
RDEA119	k TGFRb, SMAD2	MEK		
(5Z)-7-Oxozeaenol	k MP2K4, JNK	MAP3K7 (TAK1)		
Dabrafenib	k ERK, RPS6	BRAF		
THZ-2-102-1	τ cJun	CDK7->MEK, PAK1	MYC->PDK1, SMAD2	
RDEA119	τ GSK3	MEK		
HG-5-88-01	k ERK, RPS6	EGFR		
SB590885	k RSKp90, GSK3	BRAF		
Afatinib	τ ERK	EGFR; ERBB2->EGFR, SHC1, PI3K, GRB2, PAK1	MYC->PDK1, SMAD2	
(5Z)-7-Oxozeaenol	k PI3K, S6K	MAP3K7 (TAK1)		
Dabrafenib	k TGFRb, SMAD2	BRAF		
BMS-345541	τ mTOR	IKBKB	PARK2-lcJun; MYC->PDK1, SMAD2	
BMS-345541	k EGFR, TGFRb	IKBKB	PARK2-lcJun; MYC->PDK1, SMAD2	
PD-0325901	k ERK, RPS6	MEK		
BMS-345541	τ RPS6	IKBKB	PARK2-lcJun; MYC->PDK1, SMAD2	
(5Z)-7-Oxozeaenol	τ EGFR	MAP3K7 (TAK1)		
PD-0325901	k AKT, GSK3	MEK		
CI-1040	k PI3K, S6K	MEK		
HG-5-88-01	k ERK, BRAF	EGFR		
(5Z)-7-Oxozeaenol	k TAK1, JNK	MAP3K7 (TAK1)		
Afatinib	τ RPS6	EGFR; ERBB2->EGFR, SHC1, PI3K, GRB2, PAK1	MYC->PDK1, SMAD2	
PD-0325901	k PI3K, S6K	MEK		
Dabrafenib	k PI3K, AKT	BRAF		
BMS-345541	k EGF, EGFR	IKBKB	PARK2-lcJun; MYC->PDK1, SMAD2	
Trametinib	k IKK, ERK	MEK		
RDEA119	k IKK, IkBa	MEK		
BMS-345541	k AKT, PAK1	IKBKB	PARK2-lcJun; MYC->PDK1, SMAD2	
AZD6244	k AKT, GSK3	MEK		
AZD6244	τ mTOR	MEK		
SB590885	k ERK, BRAF	BRAF		
PD-0325901	τ IkBa	MEK		
Trametinib	k TGFRb, SMAD2	MEK		

B

